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Squamous cell carcinoma (SCC) is the second most common form of nonmelanoma skin cancer. In this issue
of Cancer Cell, Ehrenreiter et al. unveil a critical role for the Raf-1/Rok-a interaction in the pathogenesis of
SCCs, thus paving the way for the development of therapeutic modalities to treat this malignancy.Aberrant Ras signaling has been causally
linked to a broad spectrum of human
neoplasms. Raf kinase, the first Ras
effector to be identified, has been widely
implicated in Ras-driven tumorigenesis.
As the apical kinase in the Raf/Mek/ERK
cascade, the contribution of Raf to the
tumorigenic process has been commonly
attributed to its capacity to couple de-
regulated Ras activity to unrestrained
ERK signaling. In this issue, the study by
Baccarini and her colleagues (Ehrenreiter
et al., 2009) reveals an unexpected twist
to the involvement of Raf-1 in Ras tumor-
igenesis. By exploiting Ras-driven SCC
models, the authors have demonstrated
a critical role for Raf-1 in the initiation
andmaintenance of SCC through amech-
anism that depends on the inhibition of
the RhoGTPase target Rok-a rather than
the activation of ERK.
The Ras pathway is viewed as a central
player in SCC since the majority of these
tumors display elevated levels of active
GTP-bound Ras (Ridky and Khavari,
2004). Additionally, in mouse experi-
mental models, activating mutations of
Ras have been shown to be sufficient to
induce SCC-like tumors (Tarutani et al.,
2003). To explore the function of Raf in
Ras-driven SCC, the authors induced
the ablation of Raf-1 in two mouse
models: (1) the DMBA/TPA chemical
carcinogenesis model in which H-Ras is
activated by a codon 61 mutation muta-
tion, and (2) K5-SOS-F transgenic mice,
in which Ras activation is achieved via
the expression of a constitutively active
form of the Ras guanine nucleotide
exchange factor SOS under the control
of the full-length cytokeratin 5 (K5)
promoter. The latter model mimics SCCs
more closely because Ras is mutated in
only a small percentage (20%) of SCCbut is often activated as a consequence
of the overexpression/activation of
upstream receptor tyrosine kinases
(Ridky and Khavari, 2004). Strikingly, in
both models, Raf-1 ablation leads to inhi-
bition of tumor initiation. Moreover, Raf-1
appears to be required for tumor mainte-
nance, as ablation of Raf-1 after tumor
formation results in a pronounced tumor
regression.
How does Raf-1 loss-of-function cause
to the inhibition of tumor initiation and
regression of established tumors? Tumor-
igenesis is often thought to arise as
a consequence of an imbalance between
programs that control cell proliferation
and differentiation. However, little is
known about the determinants that coor-
dinate changes in the execution of these
programs during neoplastic conversion.
In the setting of Ras-driven SCCs, the
tumors that develop following the ablation
of one copy of Raf-1 feature an increase in
the levels of the differentiation marker
cytokeratin 10 and a decrease in the
expression of the dedifferentiation marker
Integrin b1. Moreover, tumor regression
following Raf-1 ablation is coincident
with an increase in differentiated cells. In
both settings however, the increase in
the number of differentiated cells is
accompaniedbyadecrease in thepopula-
tion of proliferating cells, making it difficult
to discern whether Raf-1 exerts its effect
on SCC tumor initiation and maintenance
by disrupting differentiation or enhancing
proliferation. To address this question,
the authors have resorted to an estab-
lished in vitro keratinocyte cell culture
system in which differentiation and prolif-
eration can be selectively manipulated.
They have found that whereas
keratinocytes derived from K5-SOS-F
mice fail to differentiate, the ablation ofCancer CeRaf-1abrogates this effectwithout notable
changes in the proliferative capacity of the
cells. While it is clear that the in vitro
system used may have certain limitations,
the most straightforward interpretation of
these findings is that the dependence of
Ras-driven SCC tumors on Raf-1 is linked
predominantly to perturbation in keratino-
cyte differentiation (Figure 1).
Next, Ehrenreiter et al. set out to define
themechanisms bywhich Raf-1 interferes
with keratinocyte differentiation. Natu-
rally, their initial attention was drawn
toward the most common Raf effector
pathway, the MEK-ERK cascade. Some-
what counterintuitively, they discovered
that Raf-1 deficiency does not compro-
mise ERK activity, indicating that, in the
context of skin homeostasis, Raf-1 func-
tion is dispensable for ERK activation. In
retrospect though, these observations
could have been expected given an earlier
study showing that loss of Raf-1 function
in keratinocytes is inconsequential for
ERK activity (Ehrenreiter et al., 2005). In
that study, it was also established that
Raf-1 binds to and inhibits Rok-a. Building
on this work, the authors now demon-
strate that this inhibitory interaction is
critical for Ras-driven SCC, as Raf-1
ablation induces Rok-a hyperactivation,
increased differentiation, and conse-
quently, restrained tumor growth (Fig-
ure 1). Furthermore, they report that
pharmacological inhibition of Rok-a is
sufficient to reverse the restraining effects
of Raf-1 ablation on tumor growth, pro-
viding proof that Raf-1-mediated Rok-a
inhibition is an essential element of the
molecular network that controls SCC
development and maintenance.
Rok-a signaling proceeds through the
phosphorylation of multiple targets, each
ofwhichcould, in principle, be responsiblell 16, August 4, 2009 ª2009 Elsevier Inc. 85
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PreviewsFigure 1. Raf-1 Promotes Ras-Induced Skin Carcinogenesis by Perturbing the Balance
between Keratinocyte Proliferation and Differentiation
Raf-1 binds to and inhibits Rok-a. This inhibition leads to heightened levels of unphosphorylated (active)
cofilin that, through a mechanism yet to be understood, stimulates STAT3 phosphorylation and Myc
accumulation. The engagement of this proposed signaling cascade culminates with the suppression of
differentiation, enhanced proliferation, and tumor promotion.WhenRaf-1 is ablated, Rok-a is free to phos-
phorylate and inactivate cofilin, and the pathway is turned off. As a result, differentiation predominates
over proliferation and tumor growth is halted.for the observed dependence of SCC
tumors on the Raf-1/Rok-a axis (Bishop
and Hall, 2000). The authors have opted
to focus on one of these targets, LIM
kinase, and its substrate cofilin. LIM
kinase-mediated phosphorylation of cofi-
lin is inhibitory, whereas the unphosphory-
lated form is active. Active cofilin has been
shown to enhance STAT3 phosphoryla-
tion, which, in turn, induces Myc expres-
sion (Honma et al., 2006). Since both
STAT3 phosphorylation and Myc accu-
mulation have been detected in human
SCC (Seethala et al., 2008) and have
been shown to promote epidermal tumor-
igenesis in animal models, it would seem
reasonable to postulate that the inhibition
of Rok-a by Raf-1 would lead to
a decrease in cofilin phosphorylation and
a corresponding increase in STAT3 phos-
phorylation and Myc accumulation. In
support of this postulate, the authors
demonstrate increased cofilin phosphory-
lation and reduced STAT3 phosphoryla-
tion and Myc expression following Raf-1
ablation (Figure 1). Pharmacological Rok-
a inhibition produces the opposite effect:
namely, decreased cofilin phosphoryla-
tion and increased STAT3 phosphoryla-
tion and Myc expression. To date, the
cofilin/STAT3/Myc pathway has not been
implicated in tumorigenesis. Hence, the86 Cancer Cell 16, August 4, 2009 ª2009 Elsfindings by Ehrenreiter et al. constitute
the first evidence for a potential role for
this pathway in skin tumorigenesis. None-
theless, given that at this point the contri-
bution of other Rok-a effectors has not
been rigorously explored, it might be pre-
mature to bet exclusively on the Rok-a/
cofilin connection.
Active Raf-1 binds to and inhibits Rok-a
function in both normal and cancer
cells. However, as this study demon-
strates, the strict dependence on this
inhibitory interaction is exhibited only by
tumorigenic skin cells that harbor an
upregulated Ras pathway. This behavior
is akin to ‘‘nononcogene addiction,’’ an
emerging concept in cancer biology
used to describe the heightened sensi-
tivity of the cancer cell to the inactivation
of normal pathways (Luo et al., 2009).
The underlying premise of this concept
is that cancer cells become addicted to
a given cellular function because this
function serves to counteract deleterious
signals. By extension, it might be argued
that SCC tumors are addicted to the
restraining effect of Raf-1 on Rok-a
because, in the presence of high Ras
signaling, Rok-a activity confers a growth
disadvantage. Sorting out the molecular
basis for this vulnerability promises to be
a challenge given the multitude of path-evier Inc.ways that are engaged in response to
unchecked Ras signaling. Furthermore,
some of these pathways impinge directly
on Rok-a function through Raf-1-inde-
pendent mechanisms (Mavria et al.,
2006), suggesting that Raf-1 might not
act alone, but rather as a component of
a broader circuitry that regulates Rok-a
activity.
There is no doubt that Ehrenreiter et al.
have just scratched the surface of defining
the cellular processes that control SCC
initiation and progression. Nonetheless,
by demonstrating that Ras-driven SCCs
are addicted to Raf-1-mediated Rok-a
inhibition, they have uncovered a unique
window of opportunity for therapeutic tar-
geting. A drug designed to selectively
interfere with Raf-1/Rok-a interaction is
likely to re-engage the disrupted differen-
tiation programs and, hence, may exhibit
antitumorigenic effects. Finally, the work
by Ehrenreiter et al. also calls for a careful
evaluation of the clinical use of Rok inhib-
itors. As clearly demonstrated, depending
on the pathological context, the outcomes
could be dire.
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